FAQ Library

FAQ Library published on July 6, 2016
Dr. Sagar Lonial discusses the need for SPEP, UPEP, and immunofixation testing in newly diagnosed multiple myeloma patients, in patients undergoing therapy, or in relapsed and refractory patients.
FAQ Library published on June 15, 2016
In this Managing Myeloma FAQ, Dr. Sagar Lonial discusses whether BD or KD should be considered a standard of care in relapsed/refractory multiple myeloma.
FAQ Library published on June 7, 2016
Join Dr. Giralt as he explains whether or not the new diagnostic criteria for multiple myeloma will cause confusion between risk of progression assessment and risk stratification for active myeloma.
FAQ Library published on May 10, 2016
In this Managing Myeloma FAQ, Dr. Sagar Lonial discusses the best indicator of improved outcomes in multiple myeloma: SCR, CR, IFCR, or MCR.
FAQ Library published on May 5, 2016
Join Paul Richardson, MD, in this Managing Myeloma FAQ as he describes true myeloma defining events and their impact on clinical practice.
FAQ Library published on April 18, 2016
Join Paul Richardson, MD, in this Managing Myeloma FAQ as he describes how to address medication compliance and adherence in the outpatient setting to oral medicines that we use in myeloma.
FAQ Library published on April 7, 2016
Join Paul Richardson, MD, in this Managing Myeloma FAQ as he briefly discusses the Revised International Staging System (R-ISS).
FAQ Library published on March 15, 2016
Join Robert Orlowski, MD, PhD in this brief Managing Myeloma FAQ as he discusses why a myeloma patient who has previous history of bone lesions should have a bone study as part of their CR assessment.
FAQ Library published on March 10, 2016
Join Dr. Sagar Lonial in this brief discussion regarding the emerging therapy classes for multiple myeloma.
FAQ Library published on February 29, 2016
Join Dr. Jatin Shah as he explains when panobinostat should be used.
Page 6 of 14
Results 51 - 60 of 140